keyword
MENU ▼
Read by QxMD icon Read
search

Vaccination against HPV

keyword
https://www.readbyqxmd.com/read/28549940/-human-papillomavirus-nonavalent-vaccine-update-2017
#1
F X Bosch, D Moreno, E Redondo, A Torné
Human papillomavirus (HPV) is the causative agent of 5% of human cancers. HPV infection is necessary for the development of cervical cancer and is responsible of a variable percentage of cancers of anus, vulva, vagina, penis, and oropharynx. Since 2007, 2 vaccines against HPV have been commercially available in Spain: bivalent (HPV types 16/18), and tetravalent (HPV types 6/11/16/18). In order to extend the protection afforded by HPV vaccines, a clinical program was launched in 2006 for the new nonavalent vaccine, including 9 HPV types (6/11/16/18/31/33/45/52/58)...
May 23, 2017: Semergen
https://www.readbyqxmd.com/read/28531261/age-of-acquiring-causal-human-papillomavirus-hpv-infections-leveraging-simulation-models-to-explore-the-natural-history-of-hpv-induced-cervical-cancer
#2
Emily A Burger, Jane J Kim, Stephen Sy, Philip E Castle
Background.: Although new human papillomavirus (HPV) infections can occur at all ages, the age at which women acquire their "causal" HPV infection that develops into cervical cancer is poorly understood and practically unobservable. We aimed to estimate the age distribution at which individuals acquired their causal HPV infection in the absence of HPV vaccination or screening to help guide the optimal use of both. Methods.: Using an empirically calibrated mathematical model that simulates the natural history of cervical cancer, we estimated the cumulative number of causal HPV infections by age, stratified by HPV genotype (HPV16 vs...
May 20, 2017: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/28528686/hpv-entry-into-cells
#3
REVIEW
Pinar Aksoy, Elinor Y Gottschalk, Patricio I Meneses
Human papillomavirus (HPV) is a sexually transmitted virus responsible for the development of cervical cancer, anal cancer, head and throat cancers, as well as genital area warts. A major focus of current HPV research is on preventing the virus from entering a cell and transferring its genetic material to the nucleus, thus potentially preventing the development of cancer. Although the available HPV vaccines are extremely successful, approximately 15 additional cancer-causing HPVs have been identified that the vaccines do not protect against...
April 2017: Mutation Research
https://www.readbyqxmd.com/read/28526738/hpv-vaccine-slashes-rates-of-oral-infection
#4
(no author information available yet)
Vaccination against human papillomavirus (HPV) reduces the prevalence of oral infection by an estimated 88% among young adults in the United States, a protection that could help reduce rates of HPV-related oropharyngeal cancers, according to data that will be presented at the American Society of Clinical Oncology Annual Meeting in Chicago, IL. However, the population-level benefit will remain low unless more people get vaccinated.
May 19, 2017: Cancer Discovery
https://www.readbyqxmd.com/read/28526331/prevalence-of-oral-human-papillomavirus-by-vaccination-status-among-young-adults-18-30years-old
#5
Jacqueline M Hirth, Mihyun Chang, Vicente A Resto
BACKGROUND: Although there is evidence that human papillomavirus (HPV) vaccination may protect against oral HPV infection, no current research has demonstrated this in the general population. METHODS: We used repeated cross-sectional data from the National Health and Nutrition Examination Survey (NHANES) between 2009 and 2014. Participants 18-30years who indicated whether they had received the HPV vaccine and provided an adequate oral sample were included (N=3040)...
May 16, 2017: Vaccine
https://www.readbyqxmd.com/read/28515303/spontaneous-and-vaccine-induced-clearance-of-mus-musculus-papillomavirus-type-1-mmupv1-muspv1-infection
#6
Rosie T Jiang, Joshua W Wang, Shiwen Peng, Tsui-Chin Huang, Chenguang Wang, Fabiana Cannella, Yung-Nien Chang, Raphael P Viscidi, Simon R A Best, Chien-Fu Hung, Richard B S Roden
Mus musculus Papillomavirus1 (MmuPV1/MusPV1) induces persistent papillomas in immunodeficient mice but not common laboratory strains. To facilitate study of immune control, we sought an outbred and immune competent laboratory mouse strain in which persistent papillomas could be established. We found that challenge of SKH1 mice (Crl:SKH1-Hrhr) by scarification on their tail with MmuPV1 resulted in three clinical outcomes: 1) persistent (>2 months) papillomas (∼20%), 2) transient papillomas that spontaneously regress typically within 2 months (∼15%), 3) no visible papillomas and viral clearance (∼65%)...
May 17, 2017: Journal of Virology
https://www.readbyqxmd.com/read/28499554/effectiveness-of-hpv-vaccines-against-genital-warts-in-women-from-valencia-spain
#7
Esther Navarro-Illana, Mónica López-Lacort, Pedro Navarro-Illana, Juan José Vilata, Javier Diez-Domingo
OBJECTIVES: To assess the effectiveness of the HPV vaccines in preventing genital warts in young women. DESIGN: Population-based study using health databases. SETTING: Valencian Community (Spain). PARTICIPANTS: All girls and women aged 14-19years who were registered in the Valencian Community between January 2009 and December 2014 (n=279,787). MAIN OUTCOME MEASURES: Incident cases of genital warts were defined as the first activation of diagnosis code ICD-9-CM 078...
June 5, 2017: Vaccine
https://www.readbyqxmd.com/read/28499288/impact-of-number-of-human-papillomavirus-vaccine-doses-on-genital-warts-diagnoses-among-a-national-cohort-of-u-s-adolescents
#8
Rebecca B Perkins, Mengyun Lin, Sherrie F Wallington, Amresh Hanchate
BACKGROUND: The impact of fewer than 3 doses of human papillomavirus (HPV) vaccine on genital warts is uncertain. METHODS: Using the Truven Health Analytics Marketscan administrative database, we compared rates of genital warts among women receiving 0, 1, 2, or 3 doses of HPV vaccine. Females aged 9 to 18 years on January 1, 2007, who were continuously enrolled in the database through December 31, 2013, were included. Patients were assigned an HPV dose state (0, 1, 2, or 3) based on the last recorded dose...
June 2017: Sexually Transmitted Diseases
https://www.readbyqxmd.com/read/28494533/awareness-of-and-attitudes-toward-human-papillomavirus-vaccination-among-adults-in-korea-9-year-changes-in-nationwide-surveys
#9
Jin-Kyoung Oh, Bo Yoon Jeong, E Hwa Yun, Min Kyung Lim
Purpose: Human papillomavirus (HPV) vaccination has been included in the National Immunization Program in Korea since 2016. We aimed to evaluate changes in the awareness of and attitudes toward HPV vaccination, among adults in Korea since the first introduction of the vaccines in 2007. Materials and Methods: A nationwide population-based survey was conducted in 2016 for 1200 nationally representative Korean men and women; the data obtained were compared with the data from the nationwide survey conducted in 2007...
May 10, 2017: Cancer Research and Treatment: Official Journal of Korean Cancer Association
https://www.readbyqxmd.com/read/28492521/coinjection-of-il2-dna-enhances-e7-specific-antitumor-immunity-elicited-by-intravaginal-therapeutic-hpv-dna-vaccination-with-electroporation
#10
Y Sun, S Peng, A Yang, E Farmer, T-C Wu, Chien-Fu Hung
The generation and use of therapeutic human papillomavirus (HPV) DNA vaccines represent an appealing treatment method against HPV-associated cervical cancer due to their safety and durability. Previously, we created a therapeutic HPV DNA vaccine candidate by linking the HPV16-E7 DNA sequence to calreticulin (CRT/E7), which we showed could generate significant E7-specific cytotoxic T lymphocyte (CTL)-mediated anti-tumor immune responses against HPV16 oncogenes expressing murine tumor model TC-1. Here we assess the therapeutic efficacy of intravaginal immunization with pcDNA3-CRT/E7 followed by electroporation...
May 11, 2017: Gene Therapy
https://www.readbyqxmd.com/read/28464900/application-of-real-time-global-media-monitoring-and-derived-questions-for-enhancing-communication-by-regulatory-bodies-the-case-of-human-papillomavirus-vaccines
#11
Priya Bahri, Julianna Fogd, Daniel Morales, Xavier Kurz
BACKGROUND: The benefit-risk balance of vaccines is regularly debated by the public, but the utility of media monitoring for regulatory bodies is unclear. A media monitoring study was conducted at the European Medicines Agency (EMA) concerning human papillomavirus (HPV) vaccines during a European Union (EU) referral procedure assessing the potential causality of complex regional pain syndrome (CRPS) and postural orthostatic tachycardia syndrome (POTS) reported to the authorities as suspected adverse reactions...
May 2, 2017: BMC Medicine
https://www.readbyqxmd.com/read/28456947/physician-communication-practices-as-a-barrier-to-risk-based-hpv-vaccine-uptake-among-men-who-have-sex-with-men
#12
Christopher W Wheldon, Steven K Sutton, Holly B Fontenot, Gwendolyn P Quinn, Anna R Giuliano, Susan T Vadaparampil
The Advisory Committee on Immunization Practices recommends that men who have sex with men (MSM) 26 years of age or younger be routinely vaccinated against HPV. For men outside of this risk-based population, the recommendation is routine vaccination until age 21. Thus, in order for this risk-based recommendation for MSM to be implemented, two distinct actions need to be completed during the clinical visit: (1) discuss recommendations for HPV vaccination with men and (2) assess sexual orientation to determine if a risk-based recommendation should be made...
April 29, 2017: Journal of Cancer Education: the Official Journal of the American Association for Cancer Education
https://www.readbyqxmd.com/read/28456141/relationship-between-the-risk-factors-for-human-papillomavirus-infection-and-lower-genital-tract-precursor-lesion-and-cancer-development-in-female-transplant-recipients
#13
Caroline Alves de Oliveira Martins, Isabel Cristina Chulvis Guimarães do Val, Luis Guillermo Coca Velarde
BACKGROUND: This study aimed to analyze the relationship between the several risk factors for human papillomavirus (HPV) infection and its persistence and to assess the prevalence of the lower genital tract precursor lesions, cancer, and HPV infection in female transplant recipients, besides the most prevalent HPV types. METHODS: The methodology adopted was a cross-sectional study with a random sample of 61 patients. RESULTS: The results indicated 10 cases (16...
April 29, 2017: Transplant Infectious Disease: An Official Journal of the Transplantation Society
https://www.readbyqxmd.com/read/28455577/-one-decade-of-hpv-vaccination-in-germany
#14
REVIEW
P Schneede
As a worldwide very common sexually transmitted infection (STI), HPV causes millions of genital warts every year and is responsible for 5% of all cancers in men and women. With strong empirical evidence for both vaccine safety and efficacy, the HPV vaccines proved to protect against these HPV-related conditions over the last decade. But current HPV vaccination coverage is suboptimal in many countries. Even in Germany the absence of a school-based immunization program and the recommendation of a publicly funded girls-only HPV vaccination strategy are the main reasons for a female coverage rate under 40%, which does not achieve herd immunity for the boys...
April 28, 2017: Der Urologe. Ausg. A
https://www.readbyqxmd.com/read/28455170/two-dose-schedules-for-human-papillomavirus-vaccine-systematic-review-and-meta-analysis
#15
REVIEW
Maddalena D'Addario, Shelagh Redmond, Pippa Scott, Dianne Egli-Gany, A Ximena Riveros-Balta, Ana Maria Henao Restrepo, Nicola Low
Simpler schedules for human papillomavirus (HPV) vaccine delivery could improve vaccine coverage and the effectiveness of cervical cancer prevention. The objective of this study was to systematically review evidence about the effects of two-dose compared with three-dose schedules for human papillomavirus (HPV) vaccine and to describe the uptake of two-dose HPV vaccination schedules globally. We searched PubMed, the Cochrane Central Registry of Controlled Trials, trials registers, and manufacturers' databases from their earliest date to February 2016...
May 19, 2017: Vaccine
https://www.readbyqxmd.com/read/28446260/human-papillomavirus-9-valent-vaccine-for-cancer-prevention-a-systematic-review-of-the-available-evidence
#16
C Signorelli, A Odone, V Ciorba, P Cella, R A Audisio, A Lombardi, L Mariani, F S Mennini, S Pecorelli, G Rezza, G V Zuccotti, A Peracino
In 2014, the Food and Drug Administration approved a new human papillomavirus 9-valent vaccine (9vHPV), targeting nine HPV types: HPV types 6, 11, 16, and 18, which are also targeted by the quadrivalent HPV vaccine (qHPV), plus five additional high cancer risk HPV types (HPV types 31, 33, 45, 52, and 58). The aim of the current study was to systematically retrieve, qualitatively and quantitatively pool, as well as critically appraise all available evidence on 9vHPV from randomized controlled trials (RCTs). We conducted a systematic review of the literature on 9vHPV efficacy, immunogenicity and safety, as well as a systematic search of registered, completed, and ongoing RCTs...
April 27, 2017: Epidemiology and Infection
https://www.readbyqxmd.com/read/28442134/hpv-vaccines-a-review-of-the-first-decade
#17
REVIEW
Diane M Harper, Leslie R DeMars
Pre-adolescent girls (9-15years) have the option of receiving a two dose HPV vaccine series at either a six month or one year interval to provide protection from HPV 16, the most prevalent type associated with cervical cancers, as well as several other less prevalent types. This series of vaccinations is highly likely to protect her from HPV infection until she enters the routine screening program, whether that be primary HPV testing or a combination of HPV testing and cytology. The two dose program has been recommended by the World Health Organization (WHO) since 2015...
April 22, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28436064/the-changing-landscape-of-cervical-screening-what-does-the-future-hold-for-primary-care
#18
L Marlow, J Waller
The landscape of cervical cancer prevention is changing in many countries thanks to the introduction of vaccination against high-risk types of human papillomavirus (HPV) and the incorporation of HPV DNA testing into cervical screening algorithms. In addition to this, uptake of screening is falling year on year in the UK and elsewhere. These factors present challenges and opportunities for health professionals working in primary care-in terms of communicating programmatic changes to women; responding to questions about the meaning and implications of HPV test results; and delivering interventions to increase screening uptake...
May 2017: European Journal of Cancer Care
https://www.readbyqxmd.com/read/28428157/texting-and-mobile-phone-app-interventions-for-improving-adherence-to-preventive-behavior-in-adolescents-a-systematic-review
#19
Sherif M Badawy, Lisa M Kuhns
BACKGROUND: Many preventable behaviors contribute to adolescent mortality and morbidity. Non-adherence to preventive measures represents a challenge and has been associated with worse health outcomes in this population. The widespread use of electronic communication technologies by adolescents, particularly the use of text messaging (short message service, SMS) and mobile phones, presents new opportunities to intervene on risk and preventive risk behavior, but little is known about their efficacy...
April 19, 2017: JMIR MHealth and UHealth
https://www.readbyqxmd.com/read/28419156/school-nurses-attitudes-towards-and-experiences-of-the-swedish-school-based-hpv-vaccination-programme-a-repeated-cross-sectional-study
#20
Maria Grandahl, Margareta Larsson, Tanja Tydén, Christina Stenhammar
The aim was to investigate school nurses' attitudes towards, and experiences of vaccination against human papillomavirus (HPV), and compare the results with a similar study three years earlier. School nurses (n = 736) from all counties in Sweden completed a questionnaire in spring 2016, four years after the implementation of the national HPV vaccination programme, and three years after the previous survey. Overall, the school nurses had more favourable attitudes towards the HPV vaccination programme compared to the study in 2013 (p = 0...
2017: PloS One
keyword
keyword
38921
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"